SLU-PP-332
The Pan-ERR Agonist Exercise Mimetic
01
Overview
SLU-PP-332 is a synthetic pan-ERR (estrogen-related receptor α, β, γ) agonist developed in Thomas Burris's laboratory, originally at The Scripps Research Institute and University of Florida. It is described as an "exercise mimetic" because it activates the same transcriptional programs the body engages during endurance exercise — driving mitochondrial biogenesis, fatty acid oxidation, and oxidative muscle fiber transformation — without requiring physical activity.
02
Mechanism of Action
SLU-PP-332 binds and activates all three estrogen-related receptors (ERRα, ERRβ, ERRγ), orphan nuclear receptors that serve as master regulators of mitochondrial energy metabolism. ERR activation upregulates genes governing oxidative phosphorylation, mitochondrial biogenesis (via PGC-1α coactivation), fatty acid β-oxidation (CPT1, MCAD), and the fast-to-slow muscle fiber shift that characterizes endurance-trained muscle. The net metabolic shift increases basal energy expenditure and fat oxidation, mimicking the adaptive response to aerobic exercise.
03
Research Highlights
Burris lab studies demonstrate significant running endurance improvement in sedentary mice without exercise training
Metabolic cage studies show increased oxygen consumption and fatty acid oxidation without reduced food intake
Diet-induced obesity models show weight reduction and improved metabolic markers following ERR agonism
04
Dosage
Administration & Timing
Oral administration (capsule or solution) or Subcutaneous (SC) injection into abdominal or gluteal subcutaneous tissue. Research protocols in animal models use once-daily oral gavage; timing independent of food.
Dosage Guidelines
Cycle Length
2–6 weeks in published animal research; no established human protocol.
05
Reconstitution
Solvent
DMSO/saline vehicle for SC research; aqueous suspension for oral
Volume
Per research formulation
Concentration
Per protocol
Storage
Store lyophilized powder at -20 °C; refrigerate solutions 2–8 °C.
Notes
SLU-PP-332 is a pan-ERR (α/β/γ) agonist and exercise mimetic. Preclinical — all published dosing is in animal models.
Research Reference Only
Dosage and reconstitution values reflect commonly cited ranges from published research literature and are presented for educational and research reference only. This is not medical advice or a dosing recommendation. HEXAGEN does not endorse human use of any compound. Always consult a qualified healthcare professional.
Research Disclaimer
SLU-PP-332 is for educational and research purposes only. Not intended as medical advice. Consult a qualified healthcare professional before making any health-related decisions.
Related Compounds
View All
SLU-PP-332 Knowledge Graph
Explore how SLU-PP-332 connects to mechanisms, research goals, related compounds, research stacks, and scientific references. Drag nodes, zoom, and filter by type.
No nodes match the active filters.
SLU-PP-332 — Common Research Questions
What is SLU-PP-332?
SLU-PP-332 is a synthetic pan-ERR (estrogen-related receptor α, β, γ) agonist developed in Thomas Burris's laboratory, originally at The Scripps Research Institute and University of Florida. It is des... SLU-PP-332 belongs to the Weight Loss research category and is studied for its the pan-err agonist exercise mimetic.
How does SLU-PP-332 work?
SLU-PP-332 binds and activates all three estrogen-related receptors (ERRα, ERRβ, ERRγ), orphan nuclear receptors that serve as master regulators of mitochondrial energy metabolism. ERR activation upregulates genes governing oxidative phosphorylation, mitochondrial biogenesis (via PGC-1α coactivation), fatty acid β-oxidation (CPT1, MCAD), and the fast-to-slow muscle fiber shift that characterizes endurance-trained muscle. The net metabolic shift increases basal energy expenditure and fat oxidation, mimicking the adaptive response to aerobic exercise.
What are the key research benefits of SLU-PP-332?
Pan-ERR (α/β/γ) agonism replicates exercise metabolic adaptation. Mitochondrial biogenesis and oxidative capacity enhancement. Increased fatty acid oxidation in skeletal muscle. Running endurance improvement in sedentary animal models. Body weight reduction without reduced food intake. Type 2 diabetes and metabolic syndrome research applications.
What is the molecular structure of SLU-PP-332?
SLU-PP-332 is a research compound in the Weight Loss category. Detailed molecular structure data is being compiled. Refer to primary literature for structural analysis.
What does the research say about SLU-PP-332?
Burris lab studies demonstrate significant running endurance improvement in sedentary mice without exercise training Metabolic cage studies show increased oxygen consumption and fatty acid oxidation without reduced food intake Diet-induced obesity models show weight reduction and improved metabolic markers following ERR agonism These findings are based on preclinical and clinical research. SLU-PP-332 is a research compound and these studies do not constitute medical advice.
Is SLU-PP-332 FDA approved?
No. SLU-PP-332 is not FDA-approved for any indication. It is a research chemical studied in preclinical and early clinical research. These compounds are not approved for human therapeutic use and should only be studied in appropriate research settings.
What category does SLU-PP-332 belong to?
SLU-PP-332 belongs to the Weight Loss category, which focuses on compounds studied for their roles in metabolic regulation, growth hormone signaling, and targeted adipose tissue reduction. You can explore more compounds in this category on the Weight Loss pillar page.
Related Articles
Tesamorelin: Clinical Data for Visceral Fat Reduction
Phase III trial data showing 15-18% visceral fat reduction and the FDA approval rationale for Egrifta®.
AOD-9604: Lipolysis Without Growth Effects
How AOD-9604's C-terminus fragment of HGH stimulates lipolysis without the growth-promoting effects of full-length HGH.
CJC-1295 + Ipamorelin: Synergistic GH Secretagogue Research
Examining the complementary mechanisms of CJC-1295 (GHRH analogue) and Ipamorelin (ghrelin mimetic) in research settings.
Scientific References
Burris lab studies demonstrate significant running endurance improvement in sedentary mice without exercise training
Metabolic cage studies show increased oxygen consumption and fatty acid oxidation without reduced food intake
Diet-induced obesity models show weight reduction and improved metabolic markers following ERR agonism